Actinium Pharmaceuticals’ (ATNM) “Overweight” Rating Reiterated at Stephens

Stephens reaffirmed their overweight rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $5.00 price target on the stock.

Actinium Pharmaceuticals Price Performance

ATNM opened at $0.98 on Tuesday. The business has a 50 day simple moving average of $1.13 and a 200-day simple moving average of $1.35. The stock has a market capitalization of $30.76 million, a P/E ratio of -0.71 and a beta of -0.21. Actinium Pharmaceuticals has a 12 month low of $0.95 and a 12 month high of $1.95.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC increased its holdings in shares of Actinium Pharmaceuticals by 278.6% in the 1st quarter. AQR Capital Management LLC now owns 63,249 shares of the company’s stock valued at $102,000 after purchasing an additional 46,545 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Actinium Pharmaceuticals by 0.9% during the third quarter. Vanguard Group Inc. now owns 1,384,543 shares of the company’s stock worth $2,215,000 after buying an additional 12,703 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Actinium Pharmaceuticals by 35.4% during the fourth quarter. Renaissance Technologies LLC now owns 390,784 shares of the company’s stock worth $531,000 after buying an additional 102,154 shares in the last quarter. Two Sigma Investments LP grew its position in Actinium Pharmaceuticals by 403.4% during the third quarter. Two Sigma Investments LP now owns 234,293 shares of the company’s stock worth $375,000 after buying an additional 187,748 shares during the period. Finally, Jane Street Group LLC acquired a new position in Actinium Pharmaceuticals during the second quarter worth about $306,000. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.